Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;16(3):267-277.
doi: 10.14740/cr2015. Epub 2025 May 7.

Epidemiology and Short-Term Outcomes of Heart Failure With Preserved and Mildly Reduced Ejection Fraction in Colombia: Insights of the Colombian Heart Failure Registry (RECOLFACA)

Lisbeth N Morales-Rodriguez  1 , Alex Rivera-Toquica  2   3   4 , Clara Saldarriaga  5 , Rolando Palacio  6 , Luis M Avila-Barros  7 , Silfredo Arrieta-Gonzalez  8 , Alfonso Munoz-Velasquez  9 , Eduardo J Echeverry-Navarrete  10 , Julian R Lugo-Pena  11 , Juan A Ceron  12 , Luis E Silva-Diazgranados  13 , Hugo E Osorio-Carmona  14 , Luis E Echeverria  15 , Juan E Gomez-Mesa  16   17
Affiliations

Epidemiology and Short-Term Outcomes of Heart Failure With Preserved and Mildly Reduced Ejection Fraction in Colombia: Insights of the Colombian Heart Failure Registry (RECOLFACA)

Lisbeth N Morales-Rodriguez et al. Cardiol Res. 2025 Jun.

Abstract

Background: Heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) has differences in therapy and development when compared with HF with reduced EF (HFrEF). We aimed to describe the clinical characteristics and all-cause mortality of patients with HFpEF/HFmrEF compared to those with HFrEF from the Colombian Heart Failure Registry (RECOLFACA).

Methods: RECOLFACA included Colombian adult patients with ambulatory HF recruited from 2017 to 2019. All-cause mortality was our main outcome. We used the Kaplan-Meier method, life table, and Cox proportional hazard models to evaluate the role of the comorbidities on mortality, with a significant P-value of < 0.05. All statistical tests were two-tailed.

Results: We included 2,514 patients, and 1,139 (45.3%) had a diagnosis of HFpEF or HFmrEF. HFpEF/HFmrEF diagnosis was not significantly related to either higher or lower risk of mortality compared to an HFrEF diagnosis; however, the individual risk factors for this outcome varied between the two groups. Health-related quality of life (HRQL) was a common risk factor for both groups.

Conclusion: Although the EF classification was not a significant risk factor for mortality, patients with HFpEF/HFmrEF exhibited a unique profile of risk factors for mortality, the HRQL, highlighting the relevance of an adequate classification of the HF patients.

Keywords: Comorbidities; Mortality; Quality of life; Systolic blood pressure; Treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they do not have any competing interests.

Figures

Figure 1
Figure 1
Clinical, echocardiographic, laboratory, and pharmacological differences between patients with HFpEF/HFmrEF and HFrEF. HFpEF: heart failure with preserved ejection fraction; HFmrEF: heart failure with mildly reduced ejection fraction; HFrEF: heart failure with reduced ejection fraction.
Figure 2
Figure 2
Kaplan-Meier survival curves comparing patients with HFpEF/HFmrEF versus HFrEF. HFpEF: heart failure with preserved ejection fraction; HFmrEF: heart failure with mildly reduced ejection fraction; HFrEF: heart failure with reduced ejection fraction.
See this image and copyright information in PMC

References

    1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM. et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596. doi: 10.1161/CIR.0000000000000757. - DOI - PubMed
    1. Ciapponi A, Alcaraz A, Calderon M, Matta MG, Chaparro M, Soto N, Bardach A. Burden of heart failure in latin america: a systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed) 2016;69(11):1051–1060. doi: 10.1016/j.rec.2016.04.054. - DOI - PubMed
    1. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J. et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574–1585. doi: 10.1002/ejhf.813. - DOI - PubMed
    1. Chaudhry SP, Stewart GC. Advanced heart failure: prevalence, natural history, and prognosis. Heart Fail Clin. 2016;12(3):323–333. doi: 10.1016/j.hfc.2016.03.001. - DOI - PubMed
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. doi: 10.1093/eurheartj/ehw128. - DOI - PubMed

LinkOut - more resources